KalVista Pharmaceuticals, Inc. (KALV)
Evaluation: Based on all recent filings, financial statements, and news.
See full evaluationAsk a question about KalVista Pharmaceuticals, Inc. (KALV)
Go deeper and ask any question about KALV
Company Performance
Current Price
as of Sep 13, 2024$11.14
P/E Ratio
N/A
Market Cap
$481.42M
Description
KalVista Pharmaceuticals, Inc. is a clinical stage pharmaceutical company, which engages in the discovery, development, and commercialization of small molecule protease inhibitors for diseases with significant unmet need. Its product candidates are inhibitors of plasma kallikrein being developed for two indications: Sebetralstat for HAE and Factor XIIa. The company was founded by T. Andrew Crockett, Edward P. Feener, and Lloyd Paul Aiello on March 26, 2004 and is headquartered in Cambridge, MA.
Metrics
Overview
- HQCambridge, MA
- SectorHealth Technology
- IndustryPharmaceuticals: Major
- TickerKALV
- Price$11.14+6.50%
Trading Information
- Market Cap$481.42M
- Float69.03%
- Average Daily Volume (1m)311,787
- Average Daily Volume (3m)339,343
- EPS-$3.54
Company
- RevenueN/A
- Rev Growth (1yr)N/A
- Net Income-$40.44M
- Gross MarginN/A
- EBITDA MarginN/A
- EBITDA-$43.99M
- EV$504.21M
- EV/RevenueN/A
- P/EN/A
- P/SN/A
Documents
SEC Filings
Factset Street Account